Andrew G. Stead

Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

Howard A. Burris, Herbert I. Hurwitz, Elizabeth Claire Dees et al. · Journal of Clinical Oncology · 2005 · 625 citations · Full text

Medicine, Oncology, Pharmacology +17

Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies

Neil L. Spector, Wenle Xia, Howard A. Burris et al. · Journal of Clinical Oncology · 2005 · 365 citations · Full text

Medicine, Oncology, Pharmacology +17

Effects of Food on the Relative Bioavailability of Lapatinib in Cancer Patients

Kevin M. Koch, Nandi J. Reddy, Roger B. Cohen et al. · Journal of Clinical Oncology · 2009 · 138 citations · Full text

Pharmacy, Oncology, Pharmacokinetics +13

Modeling the Ames test

Andrew G. Stead, Victor Hasselblad, John P. Creason et al. · Mutation Research/Environmental Mutagenesis and Related Subjects · 1981 · 126 citations

Education, Biostatistics, Educational Measurement +4

Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects

Aimee K. Bence, Eric B. Anderson, Maqbool Halepota et al. · Investigational New Drugs · 2004 · 122 citations

Pharmacy, Pharmacokinetics, Pharmacology +15